Oncogenic BRAF, unrestrained by TGFβ-receptor signalling, drives right-sided colonic tumorigenesis by Leach, Joshua D.G. et al.
ARTICLE
Oncogenic BRAF, unrestrained by TGFβ-receptor
signalling, drives right-sided colonic tumorigenesis
Joshua D. G. Leach1,2, Nikola Vlahov1, Petros Tsantoulis 3,4, Rachel A. Ridgway 1, Dustin J. Flanagan1,
Kathryn Gilroy1, Nathalie Sphyris 1, Ester G. Vázquez5, David F. Vincent1, William J. Faller 6,
Michael C. Hodder1,2, Alexander Raven1, Sigrid Fey1,2, Arafath K. Najumudeen 1, Douglas Strathdee 1,
Colin Nixon 1, Mark Hughes1, William Clark1, Robin Shaw1, S:CORT consortium*, Sander R. van Hooff7,8,
David J. Huels7,8, Jan Paul Medema7,8, Simon T. Barry9, Margaret C. Frame 10, Asier Unciti-Broceta 10,
Simon J. Leedham5, Gareth J. Inman 1,2, Rene Jackstadt1, Barry J. Thompson 11, Andrew D. Campbell 1,
Sabine Tejpar12 & Owen J. Sansom 1,2✉
Right-sided (proximal) colorectal cancer (CRC) has a poor prognosis and a distinct mutational
profile, characterized by oncogenic BRAF mutations and aberrations in mismatch repair and
TGFβ signalling. Here, we describe a mouse model of right-sided colon cancer driven by
oncogenic BRAF and loss of epithelial TGFβ-receptor signalling. The proximal colonic tumours
that develop in this model exhibit a foetal-like progenitor phenotype (Ly6a/Sca1+) and,
importantly, lack expression of Lgr5 and its associated intestinal stem cell signature. These
features are recapitulated in human BRAF-mutant, right-sided CRCs and represent fundamental
differences between left- and right-sided disease. Microbial-driven inflammation supports the
initiation and progression of these tumours with foetal-like characteristics, consistent with their
predilection for the microbe-rich right colon and their antibiotic sensitivity. While MAPK-
pathway activating mutations drive this foetal-like signature via ERK-dependent activation of the
transcriptional coactivator YAP, the same foetal-like transcriptional programs are also initiated
by inflammation in a MAPK-independent manner. Importantly, in both contexts, epithelial TGFβ-
receptor signalling is instrumental in suppressing the tumorigenic potential of these foetal-like
progenitor cells.
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Colorectal cancer (CRC)—a leading cause of cancer-relatedmortality worldwide—is a heterogeneous group of neo-plasms arising from the epithelium lining the large
intestine/colon. In recent years, the anatomical location/sided-
ness of colorectal tumours has emerged as an important deter-
minant of disease progression, response to systemic therapy, and
clinical outcome. Indeed, colorectal tumours that arise proximal
(right) or distal (left) to the splenic flexure manifest profound
differences in epidemiology, histopathogenesis, and molecular
landscapes1–3.
Left-sided CRCs develop from benign adenomas through the
conventional adenoma-carcinoma pathway typically entailing
aberrant activation of Wnt signalling, most prominently via
biallelic inactivation of the tumour suppressor APC, or activating
mutations in CTNNB1, both of which result in the stabilization
and nuclear translocation of β-catenin. Progression of pre-
malignant tubular, villous, or tubulovillous adenomas to adeno-
carcinoma is underpinned by accumulation of mutations in
oncogenes and tumour suppressor genes, such as KRAS, PIK3CA,
TP53, and SMAD4, as well as chromosomal instability4,5. Right-
sided CRCs (rCRCs) are thought to arise through an alternative
serrated neoplasia pathway so-called because the precursor
lesions—namely, hyperplastic polyps, sessile serrated adenomas/
lesions (SSAs), and traditional serrated adenomas (TSAs)—are
distinguished by a distinctive saw-tooth crypt morphology caused
by marked infolding of the upper crypt epithelium6–8. SSAs, in
particular, carry a significant risk for malignant progression6–8. In
addition to the saw-tooth crypt architecture seen in longitudinal
sections, right-sided tumours often exhibit other common his-
topathological features, including a flat/sessile morphology, and a
mucinous histology, as well as a propensity towards aggressive
local invasion with peritoneal metastases/carcinomatosis9–13.
rCRCs carry a worse prognosis than their left-sided counterparts
and are characterised by microsatellite instability (MSI) and
aberrations in MAPK, TGFβ, and mismatch repair pathways9–11.
Oncogenic mutation of BRAF, resulting in a valine-to-
glutamate substitution at residue 600 of the BRAF serine-
threonine kinase (BRAFV600E), has been identified as a key
initiating event in a sizeable subset of serrated premalignant
lesions and rCRCs14,15. Independent of upstream RAS signalling,
the BRAFV600E oncoprotein causes constitutive activation of the
MAPK (RAS-RAF-MEK-ERK) signalling cascade, which plays
key roles in cell survival, proliferation, differentiation, senescence,
and apoptosis. Previous attempts to model rCRCs, utilising
BrafV600E alone, resulted primarily in small intestinal tumours
displaying Wnt-pathway activation16–18. However, these findings
are discordant with data from patients harbouring BRAFV600E-
right-sided colonic tumours that notably lack nuclear β-catenin
positivity19. In respect of this apparent lack of Wnt-pathway
activation, recent literature has implicated the Hippo-pathway
effectors YAP/TAZ in the reprogramming and mobilization of
foetal-like, Lgr5− epithelial populations during the early stages of
colitis-associated regeneration20. In this context, Lgr5+ intestinal
stem cell (ISC) signatures are suppressed with a concomitant
increase in the expression of foetal intestinal markers, such as
Ly6a/Sca1 and Anxa1, amongst others21,22. Similarly, YAP/TAZ
signalling drives the transient foetal reprogramming that occurs
during irradiation-induced regeneration, underpinned by sup-
pression of Lgr5+ ISCs and attenuation of Wnt signalling23.
Finally, this YAP/TAZ regenerative signalling has also been
linked to the progression of APC-deficient foci to adenomas in
the murine small intestine23. As chronic inflammation, and tissue
injury and repair are associated with an elevated risk of CRC, it
remains to be seen whether this YAP/TAZ-dependent, foetal-like,
Lgr5− regenerative state plays a role in the development of right-
sided colonic tumours lacking Wnt-pathway aberrations.
To date, the lack of tractable tumour models that faithfully
recapitulate the topography and molecular landscapes of onco-
genic BRAF-driven rCRCs has hampered efforts to decipher
the underlying molecular mechanisms and develop targeted
therapeutics. Here, we describe a human-like mouse model of
right-sided colon cancer driven by oncogenic BRAF and loss of
epithelial TGFβ-receptor signalling that develops proximal colo-
nic tumours with a foetal-like progenitor phenotype (Ly6a/Sca1+)
and, importantly, lack expression of Lgr5 and its associated
intestinal stem cell signature. We further ascribe a role for
microbial-driven inflammation in the initiation of these tumours,
consistent with the long-held contention that intestinal micro-
biota are a key factor in CRC development and the pathogenesis
of right-sided disease in particular24,25. Finally, whether induced
directly by oncogenic BRAF or by inflammation, we show that the
tumorigenic potential of these foetal-like progenitor populations
is fundamentally restrained by epithelial TGFβ signalling.
Results
BRAFV600E and TGFβ-receptor loss drive Wnt-low tumours in
the right colon. Given the strong association of rCRCs with
mutations in BRAF, defects in TGFβ-receptor signalling, and epi-
genetic silencing of the mismatch repair gene MLH12, we targeted
these mutations to the murine intestinal tract. We used the
tamoxifen-inducible intestinal epithelial cell-specific VillinCreER
transgene to conditionally activate the BrafLSL-V600E knock-in allele,
or to delete the floxed alleles of the genes encoding the TGFβ-
receptor TGFBR1/ALK5 or the mismatch repair protein MLH1
(Tgfbr1/Alk5fl/fl or Mlh1fl/fl, respectively)26–28. VillinCreER; Alk5fl/fl
mice (designated A) did not develop tumours as a result of the
indicated induction regime (3mg on one occasion), while a further
cohort of 20 mice subject to a more stringent regime (3mg, 2mg
on consecutive days) did not develop tumours by 475 days (Fig. 1a).
In addition, VillinCreER; Mlh1fl/fl and VillinCreER; BrafLSL-V600E/+
(designated B) mice developed tumours predominantly in the small
intestine (Fig. 1a, Supplementary Fig. 1a, b).
We reasoned that TGFβ-receptor inactivation in human cancer
—occurring as a result of defective mismatch repair (due to a
microsatellite sequence in TGFBR2, missing from the mouse
genome)29—might synergise with mutant BRAF to initiate right-
sided colonic tumours. Indeed, VillinCreER; BrafLSL-V600E/+;
Alk5fl/fl (designated BA) mice developed tumours rapidly
compared with B mice, with median survival times of 192 and
485 days, respectively (Fig. 1a). Crucially, BA mice developed
adenocarcinomas predominantly in the proximal colon, which is
equivalent to the right colon in humans (Fig. 1b–d). Further
recapitulating rCRC, BA tumours exhibited a flat/sessile mor-
phology, mucinous differentiation, and a pronounced ability to
invade the mesentery (Fig. 1b, e).
To ensure that the preferential right-sidedness of tumours in BA
mice was not due to a regional variation in recombination
efficiency along the length of the intestinal tract, we scored
tdTomato-reporter expression in VillinCreER; Rosa26LSL-tdTomato/+
mice following varying doses of tamoxifen. Indeed, at doses of
80mg/kg, whilst emergent tumours were right-sided, the recombi-
nation efficiency was at its lowest in the colon and caecum
compared with the small intestine, highlighting that the prefer-
ential right-sidedness of tumours in this model is a result of the
specific genetic context (Supplementary Fig. 1c).
TGFβ growth-inhibitory signals are transduced through a
hetero-tetrameric receptor complex comprised of TGFBR1/ALK5
and TGFBR2 homodimers. Given that mutations in TGFBR2 are
more common than in TGFBR1 in human tumours30, we also
generated VillinCreER; BrafV600E/+; Tgfbr2fl/fl mice31. These mice
also developed primarily proximal colonic adenocarcinomas
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directly recapitulating the BA model (Supplementary Fig. 1d).
Importantly, this shared phenotype between BA and VillinCreER;
BrafV600E/+; Tgfbr2fl/fl mice ruled out the involvement of non-
canonical receptor-specific TGFβ signalling in the suppression of
right-sided tumorigenesis.
We next sought to determine whether BA tumours exhibited
Wnt-pathway activation. Unlike APC-deficient (VillinCreER;
Apcfl/+) or B tumours, BA tumours did not show nuclear β-
catenin accumulation (Fig. 1f). Furthermore, we detected
diminished expression of select Wnt-target genes (Lgr5, Axin2,
and Notum) and our previously reported Wnt-target gene
signature32, confirming that these right-sided colonic tumours
lack Wnt-pathway activation (Fig. 1f, Supplementary Fig. 2).
Using RNA-sequencing (RNA-seq) data from VillinCreER; Apcfl/fl
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intestinal tissues, harvested on day 4 post induction, we next
derived a Wnt activation (WA) signature (Supplementary Fig. 3a),
filtered to retain only epithelial genes that cluster close to AXIN2
(a prominent transcriptional target of β-catenin-dependent Wnt
signalling) in bulk human gene expression data33–35. Importantly,
this signature was significantly downregulated in patient tumours
with BRAF-mutant status compared with BRAF wild-type
counterparts, right-sided vs left-sided location, and the CRC
consensus molecular subtype (CMS) 1 (enriched for MSI and
inflammatory/immune gene expression) vs CMS2 (enriched for
genes associated with canonical Wnt signalling; Fig. 1g)36.
Collectively, these findings demonstrate that although BRAF
activation alone is not sufficient to drive tumour formation in the
right colon, concurrent loss of epithelial TGFβ-receptor signalling
cooperates in the genesis of proximal colonic tumours with
histological features of human rCRCs and attenuated Wnt/β-
catenin signalling.
BA tumours exhibit foetal-like differentiation from early
initiation. Due to the notable absence of Lgr5+ cells in BA
tumours, we next ascertained whether these tumours recapitulated
the Lgr5-independent, foetal spheroid signature21 associated with
the regenerative response that ensues following ionizing radiation
or dextran sulphate sodium salt (DSS) treatment20,23. RNA-seq
and gene set enrichment analysis (GSEA) revealed a strong
association of BA tumours with this foetal-like signature com-
pared with VillinCreER (WT) controls (Fig. 2a–c, Supplementary
Table 1). Of note, these foetal markers included Ly6a and Anxa1,
two genes highly expressed during DSS-induced regeneration20.
We also found enrichment for genes associated with an inflam-
matory response within BA tumours (Fig. 2a, right panel)37. Given
that a number of foetal markers may be expressed by stromal cells,
particularly the immune infiltrate, we confirmed epithelial cell-
specific expression of select foetal markers (Ly6a and Anxa1) via
in situ hybridization (ISH) (Fig. 2d). Interestingly, cytokeratin 7—
a keratin not normally expressed in adult intestinal epithelium, but
a component of the foetal gene program—is strongly expressed in
BA colonic tumour epithelium (Supplementary Fig. 1e). Indeed,
CK7 has been put forth as an independent marker of the serrated
pathway in CRC38.
We next addressed whether the foetal-like gene signature
emerges during tumorigenesis or whether it is present early on,
from tumour initiation. For this, we harvested proximal colonic
tissue from BA and WT mice, on day 30 (d30) post induction, and
used RNA-seq to examine the expression of the same foetal
markers at this early timepoint. Indeed, we found a significant
enrichment of the foetal-like gene signature, as well as suppression
of the Lgr5+ ISC signature22 (Fig. 2e–g, Supplementary Table 1)
in d30 BA tissues relative to the WT proximal colon. Again, we
confirmed epithelial cell-specific expression of Ly6a and Anxa1 by
ISH (Fig. 2h).
Having demonstrated low Wnt-pathway activation in rCRCs
and our BA model (Fig. 1f, g, Supplementary Fig. 2), we next
generated an analogous epithelial-specific gene signature (desig-
nated BA) from our endpoint tumour and d30 BA RNA-seq data
(Supplementary Fig. 3b). Using this BA signature to interrogate
CRC-patient datasets34,35, we identified a significant correlation
with BRAF mutation, right-sidedness, and the CMS1 subtype in
CRC-patient tumours (Fig. 3a–c). We also found a significant
inverse correlation between our BA and WA signatures and their
associated CMS subtypes in patient samples as well as a positive
correlation between our BA signature and the foetal spheroid
signature of Mustata et al.21 (Fig. 3d, Supplementary Fig. 3c).
Additionally, we observed a significant association between our
BA signature and more advanced primary tumour stage (T3–4),
consistent with the locally aggressive behaviour of our BA model
(Fig. 3e). Accordingly, our BA signature also correlated with the
shorter survival of relapsing patients and showed a trend towards
an increased frequency of peritoneal disease upon relapse (Fig. 3f,
Supplementary Fig. 3d), consistent with the pattern of metastatic
spread in patients with rCRCs12,13.
We also observed a significant enrichment of the BA signature
in sessile serrated adenomas/lesions (SSAs) compared with
tubulovillous adenomas (TVAs), the precancerous lesions of
CRCs associated with mutations in BRAF and Wnt-pathway
components, respectively (Fig. 3g, h)39. Furthermore, we found a
striking negative correlation between the WA and BA signatures
in these same precancerous lesions implying a fundamental
difference in their underlying biology from inception (Fig. 3i)39.
These data support the notion that cells expressing the foetal-like
BA signature are present from the early stages of human right-
sided tumorigenesis, in similarity with our findings in the BA
model where this signature was present from early tumorigenesis.
BRAFV600E promotes YAP-dependent foetal-like differentia-
tion. Given the central role of the transcriptional coactivator YAP
in foetal reprogramming during injury-induced regeneration20,23,
we next examined our endpoint tumour and d30 RNA-seq data to
determine whether YAP activity is associated with the foetal-like
phenotype in our BA model. Utilising the YAP target-gene sig-
nature, generated by Gregorieff et al., we identified a strong
correlation with YAP activation in both the endpoint tumour and
d30 BA colonic tissues (Fig. 4a, b, Supplementary Table 1)23.
Top-ranking genes in this YAP signature notably include foetal
markers, such as Ly6a and Anxa1, as well as classic YAP targets
such as Ctgf23.
Fig. 1 Epithelial-specific BrafV600E mutation combines with loss of TGFβ-receptor signalling to drive right-sided tumorigenesis without Wnt-pathway
activation. a Kaplan–Meier survival curves highlighting intestinal tumour-free survival (days after induction) of VillinCreER; BrafV600E/+ (B; n= 11; 3 mg
tamoxifen induction), VillinCreER; Alk5fl/fl (A; n= 3; 3 mg tamoxifen induction), and VillinCreER; BrafV600E/+; Alk5fl/fl (BA; n= 18; 2 mg tamoxifen induction)
mice. A mice were censored at 550 days post induction (indicated by tick marks on the Kaplan–Meier curve). (****p= 1.835e−7 for comparison of B vs BA;
Mantel-Cox log-rank test, two-tailed). b Representative H&E staining of BA mouse colon (n= 8) (Swiss-roll). Right, higher magnification of dashed area in
left panel, highlighting the proximal (right-sided) colonic location of adenocarcinomas. Scale bar, 500 μm. c Intestinal tumour location scoring in BA mice
(n= 11 mice). Mean ± s.e.m. (*p= 0.0194, ***p= 0.0003, ****p= 8.5e−6; Mann–Whitney U-test, two-tailed). d Schematic representing the tumour
distribution in the intestinal tract of BA mice, with circle size proportional to the regional tumour number scored in (c). Blue, caecum, and proximal colon;
Red, left colon (descending) to rectum; Diagonal line, splenic flexure. e Representative images of mesenteric invasion, with tumour epithelium highlighted
with a dotted outline (H&E; left panel), and mucin staining (Alcian Blue/PAS; right panel) in primary tumour sections from BA mice (n= 5). Scale bar, 500
μm. f Representative tumour sections, from VillinCreER; Apcfl/+, B, and BA mice (n= 5 mice per group), stained for β-catenin (immunohistochemistry) and
the Wnt-pathway activation markers Lgr5, Axin2, and Notum (ISH). Scale bar, 100 μm. g Boxplots of the Wnt activation (WA) signature in WT vs BRAF-
mutant CRCs from patients, right- vs left-sided CRCs, and across CMS subtypes. Median is shown with boxes which extend from the 25th to the 75th
percentile and whiskers which extend an additional 1.5× the interquartile range. Left panel n= 579, middle n= 604 and right n= 467 independent samples
(Left and middle panels: ***p < 0.001, T-test, two-tailed; Right panel: ***p < 2e−16, T-test, two tailed).
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We next used well-characterised and efficacious pharmacolo-
gical agents to interrogate the signalling pathways eliciting YAP
activation in our BA model. Previous studies have suggested that
the activation of YAP, triggered upon remodelling of the
extracellular matrix during DSS-induced colitis and regeneration,
is dependent on FAK signalling20. However, we were unable to
suppress the foetal program in vivo using the FAK-inhibitor
VS-471840,41 (FAKi), suggesting that mechanotransduction is not
involved in the activation of YAP in our BA model (Fig. 4c).
Evaluation of intestinal FITC-dextran uptake in both B
and BA mice revealed a significant intestinal barrier defect
(Supplementary Fig. 4b), which was associated with pronounced
proprial neutrophil infiltration in the caecum and proximal
colon (Supplementary Fig. 4c). This locoregional inflammation,
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which co-localized with the formation of tumour foci, suggested
a possible role for microenvironmental cues in triggering the
foetal-like phenotype in our BA model. We therefore generated
organoids from uninduced BA and B mice and induced gene
recombination in vitro. Importantly, under these sterile culture
conditions and in the absence of stromal influences, induction of
mutant Braf alone was sufficient to activate the foetal-like
program, accompanied by loss of Lgr5 and upregulation of foetal
markers (Fig. 4d, Supplementary Fig. 5a). In the organoid
setting, induction of foetal marker expression was not affected
by selective inhibitors of FAK (VS-4718)40,41 or SRC
(eCF506)42, but it was significantly suppressed by inhibitors of
MEK (AZD6244)43,44, ERK45, and YAP (verteporfin)20 (Fig. 4e),
with efficacy of MEK and ERK inhibitors demonstrated by
suppression of the canonical MAPK target Dusp6 (Supplemen-
tary Fig. 5b). Notably, treatment of BA mice with the MEK-
inhibitor AZD624443,44 (MEKi) markedly suppressed the
expression of foetal markers confirming the role of the MAPK
pathway in the elaboration of the foetal-like phenotype in vivo
(Supplementary Fig. 4a). Together, these results suggest that
MAPK-activating mutations directly engage with YAP signalling
and, consequently, induce foetal reprogramming in an epithelial
cell-intrinsic, ERK-dependent manner. In this regard, the
suppression of the foetal-like phenotype through YAP inhibition
in vitro raised the possibility that the foetal-like differentiation
program may be an adaptive survival mechanism directly
initiated in Braf-mutant epithelium. To test the role of YAP
in vivo using a genetics approach, we generated VillinCreER;
BrafV600E/+; Alk5fl/fl; Yapfl/fl mice. Upon tamoxifen-induction,
these mice rapidly developed weight loss and abdominal
hunching, and had to be sampled on day 6 post induction due
to these clinical signs. Histological evaluation of VillinCreER;
BrafV600E/+; Alk5fl/fl; Yapfl/fl intestinal tissues confirmed the
necessity of YAP for intestinal epithelial cell survival since, in its
absence, we detected marked epithelial necrosis that was most
pronounced in the proximal colon, although it was also evident
throughout the rest of the intestine (Fig. 4f). Consistent with
previous literature, tamoxifen-induced VillinCreER; Yapfl/fl mice
showed no discernible phenotype46, confirming that YAP is
dispensable for normal intestinal homeostasis.
We also observed that whilst Braf mutant organoids (B and
BA) induced with tamoxifen in vitro grew in Matrigel, they could
only be successfully passaged over the longer term in the presence
of PGE2, a potent inflammatory mediator that has previously
been shown to be a key component of the culture medium used to
support the passage of foetal intestinal spheroids47. Endpoint
tumour BA spheroids also exhibited this PGE2-dependency and
maintained the same foetal-like phenotype in long-term culture
as evidenced by LY6A expression and YAP1 nuclear localization
(Fig. 4g). Given the locoregional inflammation in our BA model
of right-sided colonic tumorigenesis, the requirement of exogen-
ous PGE2 for long-term organoid passage is likely significant in
light of the recently described requirement for pericryptal stromal
production of PGE2 during post-injury wound healing48. This
suggests that the combined inhibition of YAP and COX2, the
enzyme that synthesizes PGE2, may hold therapeutic promise for
the treatment of mutant BRAF-driven rCRCs.
Importantly, the ability of mutant BRAF alone to drive foetal-
like differentiation demonstrated that TGFβ signalling does not
suppress the foetal phenotype per se but, instead, independently
restrains tumorigenesis. Scoring of d30 proximal colonic tissues
for BrdU-positivity clearly showed that ablation of epithelial
TGFβ-receptor signalling has no effect on epithelial cell
proliferation (Fig. 4h). The elevated levels of apoptosis induced
by mutant BRAF in vivo, however, were suppressed following
epithelial-specific loss of TGFβ-receptor signalling, indicating
reduced sensitivity to the initiation of cell death (Fig. 4i) as has
previously been reported following loss of TGFβ-receptor
signalling49. Taken together, these findings suggest that loss of
TGFβ-receptor signalling allows colonic epithelial cells to evade
apoptosis rather than augmenting their proliferative capacity.
Right-sided tumorigenesis is supported by microbial-driven
inflammation. Our results indicate that mutant BRAF can
initiate the foetal-like phenotype in organoids, via the activation
of YAP, without additional genetic events or input from con-
textual cues. Nevertheless, the proximal colonic location of BA
tumours—a region heavily colonized by intestinal microflora—
and the presence of locoregional inflammation, evident from the
early stages of tumour initiation, raised the possibility that local
microenvironmental factors may influence tumorigenesis. Indeed,
our data showed that the integrity of the mucosal barrier is
compromised in BA tissues, likely allowing exposure of the epi-
thelium to gut microbiota and toxic metabolites that can promote
tumorigenesis by provoking inflammation24,50. To test this, we
treated BA mice with broad-spectrum antibiotics from the time of
tamoxifen-induction (Supplementary Fig. 6a). Antibiotics sig-
nificantly extended survival and reduced the tumour number in
BA mice, but this effect was only significant for right-sided
tumours (Fig. 5a, b, Supplementary Fig. 6b). Comparison of
RNA-seq analyses between antibiotic- and vehicle-treated d30 BA
mice confirmed that eleven of the top fifteen pathways, sig-
nificantly downregulated by antibiotic treatment, were associated
with inflammation and the immune response (Supplementary
Fig. 6c). Although still present, the foetal-like phenotype was
dampened, with a reduction in the expression of foetal markers,
including Ly6a, Ly6d, Krt7, and Anxa1, both in the tissue as a
whole and in the epithelial compartment specifically (Fig. 5c,
Supplementary Fig. 6d). These findings support the hypothesis
that, although BRAF mutation alone drives foetal-like
Fig. 2 Wnt-low, right-sided tumours express a foetal-like signature, present from early initiation. a GSEA plots showing enrichment of foetal spheroid
and HALLMARK inflammatory response signatures in endpoint BA colonic tumours (n= 4) vs WT proximal colon (n= 3). NES normalised enrichment
score, FDR false discovery rate. (p= 0.0, represents p < 0.001 calculated empirically.) b Heatmap showing Z-score-transformed relative expression levels
of selected foetal signature genes differentially expressed between endpoint BA intestinal tumours (n= 4) and WT proximal colonic tissue (n= 3). c qRT-
PCR of indicated foetal markers in BA intestinal tumours vs WT proximal colon (n= 4 mice per group). Mean ± s.e.m. (*p= 0.0286, compared with WT;
Mann–Whitney U-test, two-tailed). d Representative ISH of BA intestinal tumour epithelium stained for foetal markers Ly6a and Anxa1 (n= 5 mice). Scale
bar, 100 μm. e GSEA plots showing positive enrichment of the foetal spheroid signature (left panel) and negative enrichment of the Lgr5+ ISC signature
(right panel) in BA proximal colonic tissue vs WT control tissue, 30 days post induction (n= 5 per group). NES normalised enrichment score, FDR false
discovery rate. (p= 0.0, represents p < 0.001 calculated empirically.) f Heatmap showing Z-score-transformed relative expression levels of selected foetal
signature genes in BA proximal colonic tissues (n= 5), compared with WT (n= 4), 30 days post induction. g qRT-PCR of indicated foetal markers in A, B,
and BA vs WT proximal colonic tissues, 30 days post induction (n= 4 per group). Mean ± s.e.m. (*p= 0.0286, compared with WT; Mann–Whitney U-test,
two-tailed). h Representative ISH of WT and BA proximal colonic tissue, stained for foetal markers Ly6a and Anxa1, 30 days post induction (n= 5 per
group). Scale bar, 100 μm.
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differentiation, microbial-driven inflammation is an additional
key factor contributing to early tumour formation in the BA
model, and that the local microbial milieu supports tumour
initiation, right-sidedness, and disease progression. Our studies
have, therefore, established a synergistic relationship between
epithelial BrafV600E mutation, loss of TGFβ-receptor signalling,
and the local inflammatory microenvironment in driving right-
sided, foetal-like tumours.
Fig. 3 Poor-prognosis BRAF-mutant, right-sided patient CRCs are Wnt-low and express the BA signature from inception. a Boxplot showing expression
of the BA signature in WT vs BRAF-mutant CRCs from patients (n= 579). Median is shown with boxes, which extend from the 25th to the 75th percentile and
whiskers which extend an additional 1.5× the interquartile range (***p= 3.58e−5; T-test, two-tailed). b Boxplot showing expression of the BA signature of right-
vs left-sided CRCs from patients (n= 604). Median is shown with boxes, which extend from the 25th to the 75th percentile and whiskers which extend an
additional 1.5× the interquartile range (***p= 1.28e−9; T-test, two-tailed). c Boxplot showing expression of the BA signature across CMS subtypes (n= 461).
Median is shown with boxes, which extend from the 25th to the 75th percentile and whiskers which extend an additional 1.5x the interquartile range (***p=
2.16e−13; T-test, two-tailed). d Scatter plot of WA and BA signature values from human tumours showing a negative correlation (Pearson’s r=−0.232, p=
8.36e−9, two-sided) (n= 467). CMS plots are overlain highlighting the differential expression of the signatures between CMS1 and CMS2 subtypes. CMS1
(MSI-high, immune): orange; CMS2 (canonical Wnt signalling): blue; CMS3 (metabolic dysregulation): pink; CMS4 (mesenchymal): green. Median is shown
with boxes, which extend from the 25th to the 75th percentile and whiskers which extend an additional 1.5x the interquartile range. e Expression of the BA
signature is higher in T3–4 human tumours than T1–2 (***p=0.0002; T-test, two-tailed) (n= 604). Median is shown with boxes, which extend from the 25th
to the 75th percentile and whiskers which extend an additional 1.5× the interquartile range. f Patients with BA signature-high tumours (red), defined as above
the median value, have shorter survival after relapse compared with those harbouring BA signature-low tumours (blue) (***p=0.00016; Wald test, two-tailed)
(n= 197). g Expression of the WA signature is higher in tubulovillous adenomas (TVA) (n= 29) than sessile serrated adenomas (SSA) (n= 15) (***p= 1.538e
−05; T-test, two-tailed). Median is shown with boxes, which extend from the 25th to the 75th percentile and whiskers which extend an additional 1.5× the
interquartile range. h Expression of the BA signature is higher in sessile serrated adenomas (SSA) than tubulovillous adenomas (TVA) (***p= 1.498e−05; T-
test, two-tailed). Median is shown with boxes, which extend from the 25th to the 75th percentile and whiskers which extend an additional 1.5× the interquartile
range. i Higher values of the BA signature are significantly associated with lower expression values of the WA signature in pooled TVA/SSA human
precancerous lesions (Pearson’s r=−0.66, p= 1.11e−06). The regression line is presented with 95% confidence intervals (shaded area).
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Inflammation drives colonic tumorigenesis in a MAPK-
independent manner. We next sought to model the effects of
wounding and inflammation to determine whether these were
sufficient to initiate and drive tumorigenesis in B or A mice.
High-dose sulindac treatment has previously been shown to result
in proximal colonic epithelial damage51. Therefore, to provide a
brief window of inflammation/wounding, we administered
sulindac for 14 days immediately post induction (Supplementary
Fig. 7a). This acute insult was sufficient to cause tumour for-
mation in the proximal colon of A but not B mice (Fig. 5d).
Tumours in sulindac-treated A mice were almost exclusively
right-sided (Fig. 5e), consistent with the location of the injury51.
Similarly to the BA model, sulindac-treated A tumours were
invasive, exhibited a mucinous histology, and stained strongly
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positive for foetal transcripts in the epithelial compartment
(Fig. 5f, Supplementary Fig. 7b). In addition, proximal colonic
tissue harvested from sulindac-treated A mice on d30 post
induction (16 days after cessation of sulindac treatment) showed
a significant positive enrichment for the foetal-like signature and
a negative enrichment for the Lgr5+ ISC signature, as observed in
BA mice (Fig. 5g, h, Supplementary Table 1).
Given the capacity of BRAFV600E-driven MAPK activation to
engage a foetal-like program directly in vitro, we next addressed
whether MAPK activation was responsible for the foetal-like
differentiation emerging through sulindac-driven inflammation
in vivo. Utilising the MEK-inhibitor AZD6244, we demonstrated
that the instigation of the foetal-like program is likely not
dependent on MAPK activation in this inflammatory context in
WT mice (Supplementary Fig. 7c).
The ability of sulindac-induced inflammation to drive right-
sided tumorigenesis in A mice mirrored the topography of
emergent tumours in BA mice. Therefore, we next addressed
whether we could influence the location of tumour formation by
guiding inflammation to a different site. DSS has previously been
shown to drive tumorigenesis in TGFβ-receptor knockout mice52.
Using this model, we confirmed that DSS-induced inflammation
elicited tumour formation in A mice. As expected, the emergent
colonic tumours were invasive, displayed a mucinous histology,
lacked Wnt-pathway activation, and expressed foetal transcripts
in their epithelium. Importantly, these tumours were located
more distally in the colon, as would be expected with DSS
treatment (Supplementary Fig. 7d–f). Collectively, these findings
suggest that, in the presence of inflammatory stimuli driving
foetal-like epithelial differentiation, loss of TGFβ-receptor
signalling is permissive for the emergence of invasive colonic
tumours at the site of inflammation.
Discussion
An improved understanding of the molecular pathogenesis of
mutant BRAF-driven rCRCs will inform the development of
effective preventative and therapeutic strategies for this aggressive
CRC subset. Preclinical models that faithfully recapitulate the
salient features of disease initiation and progression, as bestowed
by different oncogenic drivers, are an important tool in this
endeavour. Here, we describe a mouse model of serrated intest-
inal cancer wherein oncogenic BRAF and loss of epithelial TGFβ-
receptor cooperatively promote the formation of right-sided
colonic tumours with a Wnt-low, foetal-like signature. Emergent
tumours in this model recapitulate the topography, molecular
landscape, and metastatic tropism of human right-sided disease,
lending important insights into the pathogenesis of mutant
BRAF-driven rCRCs that arise via the serrated neoplasia pathway.
While mutant BRAF-driven serrated tumours show a clear
predilection for the right side of the colon in humans, most
existing mouse models develop lesions primarily in the small
intestine rather than the colon16–18. Interestingly, Rad et al. found
that BRAFV600E induced widespread serrated hyperplasia
throughout the intestinal tract. Yet, the vast majority of hyper-
plastic polyps that progressed to dysplasia in this model were
located in the small intestine, with lesions exhibiting features of
TSAs, rather than SSAs, which the authors attributed to the fact
that SSAs typically emerge in the colon16. By contrast, BA
tumours develop in the proximal/right colon and carry a Wnt-
low, foetal-like signature which correlates with BRAF-mutant
status, right-sidedness, MSI-high, CMS1 CRCs as well as pre-
neoplastic SSAs in humans.
In further contrast to the BA model presented here, previous
serrated tumorigenesis models exhibit deregulated Wnt
signalling16–18. Notably, however, patient-derived right-sided
serrated precursor lesions rarely harbour mutations in APC or
CTNNB1, though mutations in lesser-known Wnt-pathway
components can be acquired during the progression to dysplasia/
more advanced stages53–55. Importantly though, BRAFV600E
right-sided colonic tumours in patients have been shown to dis-
play membranous not nuclear β-catenin localisation19, and we
therefore suggest that our BA model better recapitulates this
tumour group.
Previous studies employing an inducible human BRAFV600K
transgene resulted in epithelial serration and exhaustion/deple-
tion of Lgr5+ ISCs, underpinned by their conversion to transit-
amplifying (TA) progenitor cells18. By contrast, the depletion of
Lgr5+ ISCs in the BA model is accompanied by the appearance of
cells with a foetal-like phenotype. There are several differences
between these models that may account for this discrepancy.
First, the BA model develops SSA-like tumours in the proximal
colon, whereas the transgenic BRAFV600K model develops
hyperplasia and TSA-like dysplastic polyps in the small intestine.
Aside from region-specific differences in basal proliferation rates
and crypt dynamics, the signals and niche cell-types that deter-
mine cell-lineage allocation—i.e., the interconversion between
adult and foetal-like stem cell populations and TA-progenitor cell
Fig. 4 BRAFV600E drives foetal-like differentiation via YAP activation, underpinning cell viability in the proximal colon. a GSEA plots showing
enrichment of YAP up- and down-regulated gene signatures in endpoint BA tumours (n= 4) vs WT proximal colon (n= 3). NES normalised enrichment
score, FDR false discovery rate. (p= 0.0, represents p < 0.001 calculated empirically.) b GSEA plots showing positive enrichment of YAP up- and down-
regulated gene signatures in BA proximal colonic tissue vs WT control tissue, 30 days post induction (n= 5 per group). NES normalised enrichment score,
FDR false discovery rate. (p= 0.0, represents p < 0.001 calculated empirically.) c qRT-PCR of indicated foetal markers in proximal colonic tissue from
vehicle- and FAKi-(VS-4718)-treated BA mice, 30 days post induction (n= 5 mice per treatment). Mean ± s.e.m. (ns not significant; **p= 0.0079;
Mann–Whitney U-test, two-tailed). d qRT-PCR of Lgr5 and indicated foetal markers in BA organoids, induced in vitro with 4-hydroxytamoxifen and sampled
5 days post induction (n= 3 organoid lines from 3 separate uninduced BA mice). Fold change is shown relative to uninduced organoids (EtOH-treated).
Mean ± s.e.m. (*p= 0.05; Mann–Whitney U-test, two-tailed). e qRT-PCR of Ly6a in BA organoids, induced in vitro with 4-hydroxytamoxifen and sampled
48 h post drug-treatment, 5 days post induction. Drugs were reconstituted in DMSO vehicle (0.1%) at the indicated final concentrations: verteporfin (YAPi;
3 μM), AZD6244 (MEKi; 100 nM), ERKi (100 nM), eCF506 (SRCi; 50 nM), and VS-4718 (FAKi; 1 μM). n= 3 organoid lines from 3 separate uninduced BA
mice. Fold change is shown relative to DMSO-treated, induced organoids. Mean ± s.e.m. (*p= 0.05; Mann–Whitney U-test, two-tailed). f Representative
H&E-staining of the proximal colon and caecum from BrafV600E/+ Alk5fl/fl Yapfl/fl mice 6 days post induction, highlighting severe epithelial loss and
necrosis compared with BA controls (n= 5 mice per group). Scale bar, 500 μm. g Immunofluorescent staining of Matrigel ENRW-cultured BA and
VillinCre; Apcfl/+ tumour spheroids for SCA1/LY6A (green) and YAP1 (red). Nuclei were counterstained with DAPI (blue). Merged images are shown on
the right. Representative images of n= 3 biological replicates. Scale bar, 100 μm. h Image analysis scoring of the percentage of BrdU+ cells in the proximal
colon epithelium of WT (n= 6), A (n= 4), B (n= 6), and BA (n= 6) mice, 30 days post induction. Mean ± s.e.m. (ns not significant; Mann–Whitney U-
test, two-tailed). i Image analysis scoring of percentage of cleaved caspase 3+ cells in the proximal colon epithelium of WT (n= 6), A (n= 4), B (n= 6),
and BA (n= 6) mice, 30 days post induction. Mean ± s.e.m. (**p= 0.0076, Mann–Whitney U-test, two-tailed).
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states/fates—vary profoundly lengthways along the intestinal tract
and up the vertical crypt-axis56. Accordingly, BRAFV600E-mutant
small intestinal and colonic organoids differ profoundly in basal
MAPK-pathway activity, with small intestinal organoids able to
tolerate higher pathway activity upon BRAFV600E expression57.
Notably, though, the transcriptomic profiles of BRAFV600E
colonic organoids more closely resemble human BRAFV600E-
mutant CRCs57. Second, the BA model expresses physiological
levels of a knock-in BRAFV600E mutant driven by the endogenous
Braf promoter, whereas the transgenic model relies on the
overexpression of a human BRAFV600K transgene, which attains
expression of MAPK-target genes akin to levels in more advanced
dysplastic tumours. A reduction in ISC markers was also found in
the hyperplastic intestinal tissue of BRAFV637E knock-in mice,
which harbours comparable levels of MAPK activity to the
transgenic model, although a TA cell fate was not expressly
demonstrated16,18.
The conversion of the entire Lgr5+ ISC pool into TA pro-
genitor cells, in the transgenic BRAFV600K model18, is reminiscent
of normal crypt homeostasis. Therein, reduced EGFR/MAPK
Fig. 5 Inflammation and epithelial TGFβ-receptor loss cooperate in the formation of foetal-like tumours. a Kaplan–Meier survival curves highlighting
tumour-free survival (days after tamoxifen-induction) of vehicle-treated (n= 28) and antibiotic-treated (n= 28) BA mice (***p= 0.0006; Mantel-Cox log-
rank test, two-tailed). b Total number of intestinal tumours in vehicle-treated (n= 28) and antibiotic-treated (n= 28) BA mice. Mean ± s.e.m. (****p= 2.9e
−7; Mann–Whitney U-test, two-tailed). c qRT-PCR of indicated foetal markers in proximal colonic tissue from vehicle- and antibiotic-treated BA mice,
30 days post induction (n= 4 mice per treatment). Fold change is shown relative to vehicle-treated BA mice Mean ± s.e.m. (*p= 0.0286; Mann–Whitney
U-test, two-tailed). d Kaplan–Meier survival curves highlighting survival (days after induction) of sulindac-treated A (n= 5) and B (n= 3) mice. e Intestinal
tumour location scoring of sulindac-treated A mice (n= 5). Mean ± s.e.m. (ns not significant; *p= 0.0397, **p= 0.0079; Mann–Whitney U-test, two-
tailed). f Representative ISH of sulindac-treated A proximal colonic tumours, stained for foetal markers Ly6a and Anxa1 (n= 5 mice). Scale bar, 100 μm.
g GSEA plots of RNA-seq data from sulindac-treated A vs WT proximal colonic tissues, 30 days post induction, using the foetal spheroid (left panel) and
Lgr5+ ISC (right panel) gene signatures (n= 4 mice per group). NES normalised enrichment score, FDR false discovery rate. (Left panel—p= 0.0,
represents p < 0.001, Right panel—p= 0.008, calculated empirically.) h qRT-PCR of indicated foetal markers in proximal colonic tissue from sulindac-
treated A mice vs WT counterparts, 30 days post induction (n= 4 mice per group). Fold change is shown relative to untreated WT mice. Mean ± s.e.m.
(*p= 0.0286; Mann–Whitney U-test, two-tailed).
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activity at the crypt base prevents the quiescent ISC pool from
differentiating prematurely, while elevated MAPK signalling in
the upper crypt dictates a proliferative TA progenitor cell fate58.
Although the determinants underlying the different fates of
BRAF-mutant cells in these two models remain unclear, the
implications are profound: While reversion of Lgr5+ ISCs to a
foetal-like state, in the absence of TGFβ signalling, fuels aggres-
sive BA tumour growth, conversion to a TA-like state leads to
exhaustion of the cancer stem cell pool and clonal extinction. This
likely explains the finding that, in the transgenic model, the
progression of dysplastic foci was frequently accompanied by the
acquisition of Wnt/β-catenin-pathway mutations, which restored
ISC marker expression18. Indeed, this is consistent with studies
showing that BRAFV600E promotes loss of ISCs but, para-
doxically, triggers differentiation; here, oncogenic progression is
contingent on mutations that reverse differentiation (e.g. ablation
of the differentiation-promoting transcription factors CDX2 or
SMAD4) to restore stemness potential59. Accordingly, aging-
induced acquisition of epigenetic alterations predisposes to
BRAFV600E-driven transformation60, with several studies impli-
cating cooperating inactivation of Cdkn2a/p16INK4a16,
Cdx259,61, or both atypical PKCs (PKCζ and PKCλ/ι)62 in
BRAFV600E-induced tumorigenesis. Similarly, our studies identify
epithelial TGFβ-receptor signalling as an important gatekeeper to
BRAFV600E-driven right-sided tumorigenesis. Indeed, we also
show that the tumorigenic potential of foetal-like populations in
the right colon is suppressed by epithelial TGFβ-receptor sig-
nalling, independent of the factors driving the foetal-like differ-
entiation program, be it an acute inflammatory insult or aberrant
MAPK activation. Indeed, this strongly suggests that the co-
occurrence of TGFBR2 and BRAF mutations in patient rCRCs30
provides foetal-like right-sided epithelial cells with a selective
advantage.
Our study further shows that the MAPK pathway, via ERK, is
fundamentally capable of driving a foetal-like differentiation
program in the colonic epithelium in a YAP-dependent manner,
and that this is further augmented in vivo by microbial-driven
inflammation. Controversy surrounds the role of YAP in intest-
inal tumorigenesis, with both tumour-suppressive63,64 and
oncogenic roles23,65–67 ascribed in different contexts. Several
studies have demonstrated that YAP can inhibit Wnt signalling
during intestinal regeneration and tumorigenesis23,63,64,68, con-
sistent with the suppression of Lgr5 and the ISC signature in our
BA model. In strong support of our findings, while this paper was
under review, Reischmann et al. reported that the expression of
BRAFV600E in colonic organoids elicits a foetal-like dediffer-
entiation program, associated with a transcriptional signature
enriched for Hippo-pathway targets that resembles human
BRAFV600E-driven CRC57. Interestingly, activation of the ERK
and YAP pathways has also been detected in an inflammation-
driven model of serrated intestinal tumorigenesis arising through
atypical-PKC deficiency, independently of Braf (and Kras)
mutations62, signifying that YAP dysregulation may commonly
underlie distinct serrated neoplasia pathways independently of
the driver mutation.
As multiple Lgr5+ and Lgr5− populations exhibit phenotypic
plasticity and tumour-initiating potential within the intestine,
questions remain as to the likely cell(s)-of-origin of the emergent
tumours in the BA model and the serrated neoplasia pathway. A
recent study identified a rare, quiescent population of revival stem
cells, distinguished by elevated expression of clusterin (Clu) as
well as Anxa1, Cxadr, and Basp1, that is mobilized and expanded
following damage to the intestinal epithelium, regenerating all the
major intestinal cell types, including Lgr5+ ISCs, in a YAP1-
dependent manner69. It remains unclear whether different crypt
progenitors and/or mature cell types are able to dedifferentiate to
a foetal-like state in response to BRAF activation, or whether
homeostatic colonic crypt subpopulations, such as the revival
stem cells, acquire Braf mutation and initiate serrated tumor-
igenesis independently of Wnt signalling: the answer awaits
lineage-tracing and single-cell genomics approaches in our
BA model.
Our data have allowed us to identify and highlight the diverse
nature of left and right-sided CRC in patients, showing that they
are underpinned throughout tumour initiation and progression
by different signalling pathways, which lead to either a Wnt high,
Lgr5+ tumour phenotype or a BRAF-mutant, foetal-like, Lgr5-/
Wnt-low phenotype, respectively. rCRCs that harbour oncogenic
BRAF, however, continue to pose a major therapeutic challenge,
with patients deriving little to no benefit from prevailing treat-
ment regimens. While BRAF inhibitors have shown considerable
efficacy in melanoma70, BRAF-mutant rCRCs are refractory to
such treatment owing to EGFR-driven feedback activation of the
MAPK pathway71,72. Of note, the YAP-driven regenerative
response in the injured intestinal epithelium promotes cell sur-
vival by activating EGF signalling23. Accordingly, elevated YAP
expression is predictive of intrinsic and acquired resistance to
BRAF- and MEK-inhibitors in human BRAFV600E CRCs73,
lending clinical relevance to our finding that YAP is a survival
factor in BA tumours, and advocating for concurrent inhibition of
YAP and BRAF-MAPK signalling in this setting. Moreover, a
recent study in compound mutant organoids, with Rspo3-fusions
and Kras/Braf, Trp53, and Smad4 mutations, implicated YAP/
TAZ foetal reprogramming and lineage reversion in the acquisi-
tion of resistance to Wnt-targeted therapy. Significantly, emer-
gent organoids were addicted to YAP/TAZ signalling and were
sensitive to YAP/TAZ inhibition74. Encouragingly, foetal-like
colonic BA tumour epithelium also maintains a dependence on
therapeutically targetable, microenvironmental-derived inflam-
matory factors, such as PGE2. Additionally, the absolute
requirement for YAP activation in the intestinal epithelium after
BRAF mutation provides a further novel potential therapeutic
target downstream of BRAF activation.
Our BA model recapitulates the topography, molecular land-
scape, and metastatic tropism of human Wnt-low, BRAF-mutant
rCRCs and offers potential actionable therapeutic targets for this
aggressive therapy-resistant subtype.
Methods
Mouse studies. All animal experiments were performed in accordance with UK
Home Office regulations (Project licence 70/8646), with adherence to the ARRIVE
guidelines, and were reviewed and approved by the Animal Welfare and Ethical
Review Board (AWERB) of the University of Glasgow. Mice used were of a C57BL/
6 J background (N ≥ 6) and harboured combinations of the following genotypes: the
VillinCreER transgene26 Apcfl/+33, BrafLSL-V600E/+ (hereafter BrafV600E/+)27, Tgfbr1/
Alk5fl/fl28, Tgfbr2fl/fl31, Yap1fl/fl75, and Rosa26LSL-tdTomato/+76. For the generation of
Mlh1fl/fl mice, embryos carrying the Mlh1tm1a allele were imported from the Eur-
opean Mouse Mutant Archive (EM:04517). To generate the floxed allele, mice
derived from these embryos were subsequently crossed with a strain expressing Flpe
(B6.Cg-Tg(ACTFLPe)9205Dym/J; JAX stock #005703) to delete the lacZ reporter
and neomycin resistance (lacZ/neoR) cassette by recombination at the flanking FRT
sites77. Correct removal of the lacZ/neoR cassette was confirmed by PCR across the
remaining FRT site (Fwd, 5′-GTAATACTCTCTAGAGGCCCATGC-3′ and Rev,
5′-TATTAGCTCGTGGTTTTAGATGACC-3′; amplicon: 404 bp). Following Flpe-
mediated recombination, critical exon 4 of Mlh1 is flanked by loxP sites, generating
a floxed Mlh1tm1c(EUCOMM)Hmgu allele that can be conditionally deleted in the
intestine upon crossing with VillinCreER mice.
Mice were induced between 6 and 12 weeks of age and sampled at the indicated
timepoints or at clinical endpoint. Unless otherwise stated, mice were induced by
either a single intraperitoneal injection of 2 mg tamoxifen (80 mg/kg; Sigma,
T5648), or two injections of 3 mg (120 mg/kg) and 2 mg (80 mg/kg) tamoxifen on
consecutive days. Mice were monitored daily and weighed a minimum of three
times weekly and humanely culled upon reaching clinical endpoint, defined by
symptoms associated with intestinal tumour burden. Mice were censored at
550 days after initial tamoxifen-injection.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-23717-5 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:3464 | https://doi.org/10.1038/s41467-021-23717-5 |www.nature.com/naturecommunications 11
In vivo drug treatments. For antibiotic treatment, the antibiotic combination used
consisted of ampicillin (1 g/L; Sigma, A9518), neomycin trisulphate (1 g/L; Sigma,
N6386), vancomycin (500 mg/L; Wockhardt, 17116), and metronidazole (1 g/L;
Sigma, M1547), dissolved in distilled water. From the first day after the initial
tamoxifen-injection, mice were treated with antibiotics in their drinking water,
which was changed three times weekly. High-dose sulindac was administered in the
drinking water (0.4 g/L in sodium phosphate buffer; Sigma, S8139) from the first
day after the initial tamoxifen-injection, for a total of 14 days, before returning the
mice to normal drinking water. Sulindac, in drinking water, was delivered in dark
bottles, which were changed weekly along with the sulindac. For the induction of
inflammation, mice received dextran sulphate sodium salt (DSS; MP Biomedicals,
160110) in distilled drinking water on day 3 after the initial tamoxifen-injection.
DSS (1.5% w/v in drinking water) was administered ad libitum for five days and,
subsequently, withdrawn and replaced with fresh distilled water. For in vivo FAK
inhibition40,41, mice were treated with 18.75 mg/kg VS-4718 reconstituted in 0.5%
hydroxypropyl methylcellulose (HPMC)+ 0.1% Tween-80 vehicle by oral gavage
once daily. For in vivo MEK inhibition43,44, mice were treated with 25 mg/kg
AZD6244 made up in the same vehicle as VS-4718, but administered by twice-daily
oral gavage.
FITC-dextran gut permeability assay. Mice were induced with two injections of
3 mg (120 mg/kg) and 2 mg (80 mg/kg) tamoxifen on consecutive days. On day 7
post induction, mice were fasted for 12 h and then dosed with 600 mg/kg FITC-
dextran (4 kDa; Sigma, #46944) by oral gavage. Mice were sacrificed and blood was
sampled 4 h post gavage. Serum concentrations of FITC-dextran were determined
using a fluorimeter (490/530 nm) against standard curves generated from the same
stock solution used to dose the mice.
Immunohistochemistry, in situ hybridization, and histopathology. Intestinal
tissues were fixed in 10% neutral-buffered formalin overnight and embedded in
paraffin. Haematoxylin-and-eosin (H&E) staining was performed using standard
protocols. Immunohistochemistry (IHC) for cytokeratin-7 (1:100; Abcam, ab9021),
cleaved caspase 3 (1:500; Cell Signaling Technology, 9661), BrdU (1:150; BD
Biosciences, 347580), and RFP (1:100; Cell Signaling Technology, 2555), to detect
tdTomato and evaluate the efficiency of Cre-mediated recombination, were per-
formed on 3 μm sections with heat-based antigen retrieval at pH 6 and pH 8,
respectively. For β-catenin IHC, fixation was performed at 4 °C for no more than
24 hours, and sections were immunostained with antibodies against β-catenin
(1:50; BD Biosciences, 610154)78. RNA in situ hybridisation (ISH) was performed
using the RNAscope 2.5 LS Reagent Kit–BROWN (Advanced Cell Diagnostics,
322100) on a Leica Biosystems BOND RX automated IHC/ISH stainer according to
the manufacturer’s instructions. Positive control probes (Mm-PPIB; Advanced Cell
Diagnostics, 313918) were run to ensure RNA integrity in analyzed samples.
Negative control probes were run to ensure the specificity of the staining (dapB;
Advanced Cell Diagnostics, 312038). The RNAscope probes used were: Notum
(428988), Axin2 (400338), Lgr5 (312178), Ly6a (427578), and Anxa1 (509298).
Tumours were scored by gross examination of the excised tissue and
histopathological analysis of H&E-stained sections. The proximal/right side of the
colon was defined as the region extending from the ileocolic junction to the distal
end of the region of the colon containing prominent transverse folds. The left side
consisted of all colonic regions distal to this point. H&E-stained intestinal sections
were evaluated for sub-cryptal proprial neutrophil infiltration by a boarded
pathologist (J.D.G.L.). Neutrophils were identified by nuclear morphology and
cytoplasmic tinctorial properties. The numbers of neutrophils within the band of
lamina propria, immediately beneath and surrounding the colonic crypts, were
quantified by image capture and analysis of H&E-stained tissue sections.
Normalizing to the width of a 400x magnification field of view (FOV) of the colon
crypts and the surrounding lamina propria allowed for the quantification and
normalisation of neutrophil numbers within an area of tissue likely to expand in
depth following significant immune infiltration. Ten to twenty 400x FOV were
scored per region depending on length of region.
Using RFP immunohistochemistry, the efficiency of Cre-mediated
recombination was scored in VillinCreER; Rosa26LSL-tdTomato/+ mice receiving
escalating tamoxifen-dosing regimens, as indicated in Supplementary Fig. 1c.
Crypts were scored as positive when an area greater than, or equal to, half of the
crypt stained positive for RFP. At least 50 crypts were scored per mouse per
tamoxifen-dosing regimen in 3 independent VillinCreER; Rosa26LSL-tdTomato/+ mice.
Immunohistochemistry images were scanned and subsequently analyzed using
HALO software (V2.0.1145, Indica Labs). Proximal colonic epithelium was
manually annotated to include all epithelium visible and then analyzed for the
percentage of positive cells for cleaved caspase 3 or BrdU.
RNA isolation from tissue. Tumours and proximal colonic tissues were harvested
into RNAlater and snap-frozen on dry ice. Tissues were homogenized using the
Precellys lysing kit (Bertin Instruments, KT03961-1-003-2) in a Precellys Evolution
tissue homogenizer. RNA was extracted and purified, using the Qiagen RNeasy
Mini kit (Qiagen, 74104), as per the manufacturer’s protocol, including all
optional steps.
qRT-PCR. cDNA was generated using the High-Capacity cDNA Reverse Tran-
scription Kit (ThermoFisher Scientific, 4368814) as per the manufacturer’s pro-
tocol. qPCR was performed using the Maxima SYBR Green/ROX qPCR Master
Mix (ThermoFisher Scientific, K0221) as per the manufacturer’s protocol on
Applied Biosystems StepOnePlus PCR system using StepOne software version 2.3
(qPCR). Ct-values were normalised to Gapdh transcript levels. mRNA expression
levels were calculated via the ΔΔCt method utilising Microsoft Excel 2016. For
primer sequences please see Supplementary Table 2.
RNA-seq and data analysis. RNA quality was ensured utilising the Agilent 2200
TapeStation System and RNA ScreenTape (Agilent, 5067-5576). Libraries for DNA
sequencing were prepared utilising a method adapted for the Illumina TruSeq RNA
LT Kit. The quality of DNA libraries was established using the Agilent 2200
TapeStation. Library sequencing was run on the Illumina NextSeq 500 desktop
sequencer using the High Output 75-cycle kit (2 ×36 cycles). Quality checks on the
raw RNA-Seq data files were done using FastQC version 0.11.8, then sequences
were trimmed to remove adaptor sequences and low-quality base calls, defined as
those with a Phred score of less than 20, using Trim Galore version 0.6.4. Trimmed
paired-end reads were then aligned to the GRCm38.98 version of theMus musculus
genome using HISAT2 version 2.1.0 and raw counts per gene were determined
using FeatureCounts version 1.6.4. Differential expression analysis, based on the
negative binomial distribution, was performed using the R package DESeq2 version
1.22.2. Gene set enrichment analyses (GSEA) were performed on pre-ranked RNA-
seq datasets using the Broad Institute GSEA tool (software.broadinstitute.org/gsea/
index.jsp) with standard settings. The gene sets used included the foetal spheroid
upregulated signature21, the Hallmark Inflammatory_Response gene set (Broad
Institute)37, the YAP up- and down-regulated signatures23, and the Lgr5 intestinal
stem cell signature22. Pathway analysis was performed utilising MetaCore (Clar-
ivate Analytics).
Organoid cultures. Advanced DMEM/F12 was supplemented with penicillin (100
U/ml) and streptomycin (100 µg/ml) (ThermoFisher Scientific, 15140122), 2 mM
L-glutamine (ThermoFisher Scientific, 25030081), 10 mM HEPES (ThermoFisher
Scientific, 15630080), N2-supplement (ThermoFisher Scientific, 17502001) and
B27-supplement (ThermoFisher Scientific, 17504044) and designated as ADF.
Complete ADF was prepared from ADF by adding 50 ng/ml recombinant human
EGF (Peprotech, AF-100-15), 100 ng/ml recombinant murine Noggin (Peprotech,
250-38), and 500 ng/ml recombinant mouse R-spondin-1 (R&D systems, 3474-RS).
For wild-type colonic organoid culture, complete ADF was further supplemented
with 2.5 μM CHIR99021 (Sigma, SML1046), 1 μM valproic acid (Sigma, P4543),
and 10 μM Y-27632 (Cambridge Bioscience, SMO2-1). For serial passaging of
induced (tamoxifen-treated) or tumour BA organoids, the medium was further
supplemented with 2.5 μM PGE2 (Tocris Bioscience, 2296).
For in vitro BA organoid drug treatments, organoids were induced with 5 μM 4-
hydroxytamoxifen (Sigma, #T5648) 24 h post passage. BA organoids were then
treated with drug 48 h post induction and harvested for analysis 48 h post drug
addition. All drugs were made up in DMSO, at a final concentration of 0.1%, which
served as a vehicle control. Final drug concentrations were: VS-471840,41 (FAKi) at
1 μM, eCF50642 (SRCi) at 50 nM, AZD624443,44 (MEKi) at 100 nM, ERKi45 at 100
nM, and verteporfin20 (YAPi) at 3 μM.
Colonic organoid isolation and culture were performed as previously
reported79. Briefly, for the isolation of tumour organoids, murine intestinal tumour
tissue was sampled at a defined endpoint, cut into small fragments with forceps and
scissors, and washed five times in PBS. Tumour fragments were incubated in 5 ml
of 10x trypsin (5 mg/ml; Gibco), 1x DNase I buffer, and 200 U recombinant DNase
I (Roche, 04716728001) for 30 minutes in a 37 °C water bath. Tumour fragments
were, then, further dissociated in 5 ml ADF with vigorous shaking. This step was
repeated five times. The tissue suspension was then centrifuged at 260 g, and the
supernatant was aspirated and the pellet was resuspended in 10 ml ADF. The
resulting suspension was then passed through a 70 µm cell strainer and centrifuged
at 260 × g. The cell pellet was resuspended in an amount of Matrigel (BD
Bioscience, 354234), proportional to the pellet volume, and seeded. Organoids/
spheroids were cultured in complete ADF supplemented with a cocktail of growth
factors appropriate to each genotype, as detailed above, and maintained at 37 °C in
a humidified atmosphere of 5% CO2 and 21% O2.
Organoid immunofluorescence. Organoid immunofluorescence was performed in
accordance with previously published methods80. Briefly, whole organoids were
dissociated from matrigel, washed in PBS and fixed with 4% PFA on ice. Organoids
were blocked for 1 hr at room temperature (1% BSA/PBS) and stained overnight at
4 °C with the following primary antibodies: rat anti-SCA1/LY6A (1:100; R&D
Biosystems, 177228) and rabbit anti-YAP (1:100; Cell Signaling Technology, 4912).
Organoids were exposed to Alexa Fluor 488 Goat anti-rabbit IgG or Alexa Fluor
594 goat anti-rat IgG (Invitrogen, 1/500) 2 hours at room temperature and
counterstained with DAPI. Z-stack fluorescent and brightfield images were taken
on a Zeiss 710 confocal microscope. Image analysis and Z-projection were per-
formed using FIJI software and brightness and contrast settings were maintained
between control and test images.
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Statistical analyses. Statistical analyses were performed using GraphPad Prism
software (v8.02; GraphPad Software Inc.) and R (version 3.6.0; www.r-project.org/).
Generation of gene signatures through differential gene expression analysis was
performed with edgeR version 3.28.1 and the limma R package81. Human ortho-
logues of mouse genes were obtained from Ensembl in March 2020. T-test and
Mann–Whitney U-tests were used to determine statistical significance as appro-
priate. Survival analysis was based on Kaplan–Meier curves and univariable Cox-
models were built for statistical testing with the log-rank test.
CRC-patient data for in silico analysis. CRC-patient data were obtained from a
range of publicly available sources. Expression data and clinical/genetic annotation
from the TCGA project82 were downloaded from the FIREHOSE repository
(https://gdac.broadinstitute.org/). Patient-derived CMS signatures were derived
from the TCGA dataset (https://www.cancer.gov/tcga). Gene expression data from
human colorectal tumours, sampled during the PETACC-3 trial, were found in
ArrayExpress (Accession No: E-MTAB-990)34. Single-cell RNA-seq data, used to
derive a list of epithelial-specific genes, can be found in ref. 35. The polyp dataset (n
= 44) was collected by the S:CORT consortium (Ethics: MREC 15/EE/0241). Data
relating to transcriptome profiling of relevant genes are available online (https://
www.s-cort.org/)39.
BA and WA signature derivation. The derivation of gene expression signatures
was based on genes that were differentially expressed in mouse datasets at an
absolute logFC>2 and an unadjusted p value of <0.00001 in an edgeR model
incorporating batch and gene activation status. These genes were mapped to the
most confident human orthologues, based on the Ensembl annotation (March
2020). The genes were further classified into epithelial, non-epithelial, and non-
specific, according to the specificity of their expression in a previously published
human colorectal single-cell dataset35. Briefly, cells were annotated into major
types with SingleR. Then, raw counts from cells of a similar type (epithelial, stroma,
myeloid, lymphocytes, endothelial, and other) were aggregated into pseudobulk
with the muscat package. If the expression of a gene was higher in a given cell type
than in all other cell types by at least 1 raw count, and that difference was always
statistically significant at p < 0.01, the gene was considered specific for that cell type.
For the BA signature, both an upregulated and downregulated epithelial
component were retained, and the difference in their mean expression levels
comprised the signature value. For the WA signature, in order to increase
specificity, the upregulated epithelial component was mapped to a heatmap of
human colorectal cancer bulk gene expression data (E-MTAB-990 in
ArrayExpress) with hierarchical clustering on correlation distance and complete
linkage. The most significant cluster of epithelial genes was centred on AXIN2 in
the human data and was considered specific for Wnt activation. The mean
expression of the genes (MACC1, KRT23, FGFR4, RPS6KA6, PROX1, ASCL2,
AXIN2, RASSF10) constitutes the WA signature.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All data relevant to this study are available from the authors at reasonable request. The
RNA-seq datasets that support the findings described here have been deposited at NCBI
Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo) with the study accession
code GSE168478. All source data are available as a Source Data file. The remaining data
are available within the Article, Supplementary Information or from the authors upon
request. Source data are provided with this paper.
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